A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Locally Advanced Solid Tumors Metastatic Solid Tumors Lymphoma Primary CNS Tumors ALK ROS1 NTRK1-3 Primary CNS tumor anaplastic large cell lymphoma metastatic solid tumor advanced solid tumor sarcoma infantile fibrosarcoma glioblastoma soft tissue schwannoma solitary fibrous tumor glioma inflammatory myofibroblastic tumor pediatric Neoplasms Central Nervous System Neoplasms Oral repotrectinib (TPX-0005) Repotrectinib (TPX-0005)
Lead Scientist at University of California Health
- Noah Federman, MD (ucla)
HS Clinical Professor, Pediatrics. Authored (or co-authored) 72 research publications. Research interests: hematology/oncology · sarcomas · bone and soft tissue cancers · pediatrics · pediatric tumor oncology · nanotechnology.
- accepting new patients
- Start Date
- Completion Date
- Turning Point Therapeutics, Inc.
- Phase 1/2
- Study Type
- Last Updated